Quantcast

Latest Obstructive lung disease Stories

2014-06-26 16:25:01

HAMPTON, N.J., June 26, 2014 /PRNewswire/ -- Bellerophon Therapeutics LLC, a clinical stage biotherapeutics company, today announced that it has completed enrollment of its 159-patient Phase 2 clinical trial of INOpulse for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). PH-COPD is a serious complication of COPD that can significantly affect the health status of patients with this condition. Current standard of care is primarily...

2014-06-18 12:32:44

--Data indicate ASM-024 DPI safe and generally well-tolerated in asthma-- QUEBEC CITY, Quebec, June 18, 2014 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced top-line results from a combined Phase 1 and 2a trial evaluating its lead compound, ASM-024, in moderate asthma patients. The data comes from Asmacure's recently...

healthy diet for COPD
2014-05-22 07:32:40

April Flowers for redOrbit.com - Your Universe Online An international team of researchers has discovered a direct link between eating fish, fruit and dairy products with improved lung function in patients with chronic obstructive pulmonary disease (COPD). The study, which is being presented at the American Thoracic Society (ATS) 2014 International Conference, specifically examined COPD patients' lung function within 24 hours of consuming fish, cheese, grapefruit and bananas. "Diet is a...

2014-04-30 20:23:46

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK's first once-daily anticholinergic, a type of...

2014-04-23 23:04:20

New research report “COPD Drug Market Opportunity & Clinical Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com. According to the study, the world COPD market is predicted to grow at a CAGR of nearly 8% and reach USD 17.5 billion by 2018. London, UK (PRWEB) April 23, 2014 Around 1 billion people across the globe suffer from pulmonary or respiratory diseases. Within the respiratory therapeutic domain, chronic obstructive pulmonary disease...

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...

Yoga Can Help Patients With COPD Improve Lung Function
2013-10-29 06:18:51

April Flowers for redOrbit.com - Your Universe Online A new study from researchers at the All India Institute of Medical Sciences, Department of Pulmonary Medicine and Sleep Disorders reveals that patients with COPD can improve their lung function by practicing yoga. The study found that lung function, shortness of breath and inflammation all demonstrated significant improvement after patients completed 12 weeks of yoga training. The study results were presented at CHEST 2013, the...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related